drugset

drugset / Trial / NCT00475644

A Study of Enzastaurin in Participants With Follicular Lymphoma

NCT00475644 ↗

Phase 2 Completed 66 enrolled Eli Lilly and Company

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the antitumor activity, as measured by tumor response rate, of enzastaurin in participants with Follicular Lymphoma (FL).

Timeline

Start: 2007-05
Primary completion: 2012-04
Completion: 2014-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	enzastaurin	Small molecule	500 mg	Oral

Indications